Pembrolizumab

Evidence Level: L5

Predicted Indications: 9

Pembrolizumab

Pharmacist Assessment Report

Pembrolizumab: From Non-Small Cell Lung Cancer and Metastatic Melanoma to Fibromatosis, Gingival

One-Sentence Summary

Pembrolizumab is a PD-1 immune checkpoint inhibitor, originally used to treat non-small cell lung carcinoma, lung cancer and metastatic melanoma. The TxGNN model predicts it may be effective for gingival fibromatosis, but no clinical trials and no publications were found for this indication, so the prediction rests on model output alone.

Quick Overview

Item	Content
Original Indication	Non-small cell lung carcinoma, lung cancer, metastatic melanoma (the India licence record has no approved-indication text)
Predicted New Indication	Fibromatosis, gingival
TxGNN Prediction Score	0.9940
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Pembrolizumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1, encoded by PDCD1). Its efficacy in lung cancer and melanoma is well established, and it has been approved for many other cancers.

Gingival fibromatosis is a benign overgrowth of gum tissue. PD-1 blockade works by reactivating T-cell responses against tumours, and there is no established mechanistic rationale for applying it to a benign fibrous overgrowth. The high TxGNN score (0.994) is a model prediction only. It is not supported by any trial or publication.

The other top-ranked predictions show the same pattern. Most have no evidence, and those with literature (such as lung benign neoplasm) are matched on malignant lung cancer studies that do not apply to the predicted disease. The predictions appear to be driven largely by the original lung cancer indications.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
Registration No. 115727	Keytruda Injection (MSD Pharmaceuticals Pvt Ltd)	Vial of 4 ml injection	Not specified in the available record

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-PD-1 monoclonal antibody), not a conventional cytotoxic agent
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions. Literature on pembrolizumab reports immune-related adverse events, including endocrine, thyroid, neurological and myocarditis events, so routine monitoring of endocrine, liver and thyroid function is generally advisable
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions (13 interactions recorded in the interaction databases):

Major: lenalidomide, pomalidomide, thalidomide
Moderate: corticosteroids, namely hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone, methylprednisolone and deflazacort
Pharmacology data also confirm that the drug’s target is PD-1 (CD279).

Package insert warnings and contraindications for the India product were not available. Please refer to the package insert for further safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for gingival fibromatosis is supported only by a model score. There are no trials or publications, and there is no plausible mechanism linking PD-1 blockade to a benign gingival overgrowth. Evidence is graded L5.

To proceed, the following is needed:

Mechanistic or preclinical evidence linking PD-1 signalling to gingival fibromatosis
Mechanism of action (MOA) data from DrugBank
Package insert warnings and contraindications for the India product, which are currently missing
A safety assessment of immune-related adverse events in a benign, non-oncology population
Reconsideration of other candidates in the ranking (for example, lung hilum carcinoma or pulmonary sulcus neoplasm), which are anatomical or histological subsets of already-approved lung cancer indications and may be better-founded than this prediction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.